Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With S

Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTPStrong Commercial Execution Maximizing Value of Existing Portfolio:ENTYVIO® Pen Launched in U.S. for Ulcerative Colitis; U.S. FDA Approval Decision...

Related Keywords

United States ,Japan ,Osaka ,Christopher Oreilly ,Actual Exchange Rate ,Constant Exchange Rate ,International Financial Reporting Standards ,Exchange Commission ,Digital Technology ,Takeda Pharmaceutical Company Limited ,Ultra Rare Blood Clotting Disorder ,Commercial Execution Maximizing Value ,Existing Portfolio ,Pen Launched ,Ulcerative Colitis ,Disease Filing Expected ,Dengue Vaccine Now Launched ,Chinafor Refractory Post Transplant ,Operating Profit Change ,Reflecting Generic Impact ,Lower Coronavirus Vaccines Revenue ,Increased Investment ,Cycle Management Approvals ,January Support Forward Momentum ,Launch Products ,Costa Saroukos ,Management Guidance ,Free Cash Flow ,Annual Report ,Score Revenue ,Core Operating Profit ,Core Net Profit ,Net Debt ,Free Cash ,